These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17089447)

  • 21. The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice.
    Sukumari-Ramesh S; Alleyne CH; Dhandapani KM
    Transl Stroke Res; 2016 Apr; 7(2):141-8. PubMed ID: 26338677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Panobinostat (Farydak) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
    [No Abstract]   [Full Text] [Related]  

  • 23. Animal models for muscular dystrophy: valuable tools for the development of therapies.
    Allamand V; Campbell KP
    Hum Mol Genet; 2000 Oct; 9(16):2459-67. PubMed ID: 11005802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic trials on progressive muscular dystrophy.
    Satoyoshi E
    Intern Med; 1992 Jul; 31(7):841-6. PubMed ID: 1450492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
    Hainsworth JD; Infante JR; Spigel DR; Arrowsmith ER; Boccia RV; Burris HA
    Cancer Invest; 2011 Aug; 29(7):451-5. PubMed ID: 21696296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of muscular dystrophies.
    Kingston WJ; Moxley RT
    Gen Pharmacol; 1989; 20(3):263-8. PubMed ID: 2663627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
    Cheng T; Grasse L; Shah J; Chandra J
    Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC inhibitors overcome first hurdle.
    Garber K
    Nat Biotechnol; 2007 Jan; 25(1):17-9. PubMed ID: 17211382
    [No Abstract]   [Full Text] [Related]  

  • 30. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
    Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
    J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients.
    Terpos E
    Leuk Res; 2011 Mar; 35(3):295-6. PubMed ID: 21093911
    [No Abstract]   [Full Text] [Related]  

  • 32. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
    Stegmann DA
    Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Drug Discov Today; 2019 Mar; 24(3):685-702. PubMed ID: 30776482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beleodaq approved for rare lymphomas.
    Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allopurinol for muscular dystrophy.
    Griffiths JR; Shuttlewood RJ
    Lancet; 1980 Aug; 2(8191):423-4. PubMed ID: 6105542
    [No Abstract]   [Full Text] [Related]  

  • 37. Panobinostat approved for multiple myeloma.
    Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
    Cantley MD; Fairlie DP; Bartold PM; Marino V; Gupta PK; Haynes DR
    Rheumatology (Oxford); 2015 Sep; 54(9):1713-23. PubMed ID: 25832610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies.
    Russo V; Papa AA; Williams EA; Rago A; Palladino A; Politano L; Nigro G
    Trends Cardiovasc Med; 2018 Jul; 28(5):330-337. PubMed ID: 29292032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.